Metastatic, castration-resistant prostate cancer with a BRCA1, BRCA2, or ATM alteration and who had disease progression after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI)
Rucaparib (n=270) vs. SOC (n=135)
Efficacy
BRCA1/2 mutant subgroup
mrPFS: 11.2 vs. 6.4 mos, p<0.001
İTT group
mrPFS: 10.2 vs. 6.4 mos, p=<0.001
Safety
Any grade: fatigue (61.% vs. 63%), nausea (50% vs 19%), anemia (47% vs 18%), diarrhea (31% vs. 28%)
Grade≥3 AEs: anemia (24% vs. 1%), fatigue (7% vs. 9%).
